Connection

Co-Authors

This is a "connection" page, showing publications co-authored by CANDELARIA GOMEZ-MANZANO and JUAN FUEYO-MARGARETO.
  1. Gene therapy. Handb Clin Neurol. 2012; 104:331-8.
    View in: PubMed
    Score: 0.409
  2. Oncolytic adenoviruses for the treatment of brain tumors. Curr Opin Mol Ther. 2010 Oct; 12(5):530-7.
    View in: PubMed
    Score: 0.375
  3. Interspecies adenovirus fiber shows "evolutionary" advantage for oncolytic therapy of gliomas. Cancer Biol Ther. 2008 May; 7(5):794-6.
    View in: PubMed
    Score: 0.317
  4. Delta-24 increases the expression and activity of topoisomerase I and enhances the antiglioma effect of irinotecan. Clin Cancer Res. 2006 Jan 15; 12(2):556-62.
    View in: PubMed
    Score: 0.271
  5. Genetically modified adenoviruses against gliomas: from bench to bedside. Neurology. 2004 Aug 10; 63(3):418-26.
    View in: PubMed
    Score: 0.245
  6. A novel E1A-E1B mutant adenovirus induces glioma regression in vivo. Oncogene. 2004 Mar 11; 23(10):1821-8.
    View in: PubMed
    Score: 0.238
  7. [Molecular control of the cellular cycle and apoptosis: new treatments for gliomas]. Neurologia. 1998 Aug-Sep; 13(7):349-55.
    View in: PubMed
    Score: 0.161
  8. Oncolytic Adenovirus and Tumor-Targeting Immune Modulatory Therapy Improve Autologous Cancer Vaccination. Cancer Res. 2017 07 15; 77(14):3894-3907.
    View in: PubMed
    Score: 0.149
  9. C-Jun N-terminal kinases are required for oncolytic adenovirus-mediated autophagy. Oncogene. 2015 Oct 08; 34(41):5295-301.
    View in: PubMed
    Score: 0.127
  10. Intratumoral heterogeneity and intraclonal plasticity: from warburg to oxygen and back again. Neuro Oncol. 2014 Aug; 16(8):1025-6.
    View in: PubMed
    Score: 0.122
  11. Delta-24-RGD oncolytic adenovirus elicits anti-glioma immunity in an immunocompetent mouse model. PLoS One. 2014; 9(5):e97407.
    View in: PubMed
    Score: 0.120
  12. Anti-vascular endothelial growth factor therapy-induced glioma invasion is associated with accumulation of Tie2-expressing monocytes. Oncotarget. 2014 Apr 30; 5(8):2208-20.
    View in: PubMed
    Score: 0.120
  13. Targeting brain tumor stem cells with oncolytic adenoviruses. Methods Mol Biol. 2012; 797:111-25.
    View in: PubMed
    Score: 0.102
  14. The E1B19K oncoprotein complexes with Beclin 1 to regulate autophagy in adenovirus-infected cells. PLoS One. 2011; 6(12):e29467.
    View in: PubMed
    Score: 0.102
  15. [Wernicke's encephalopathy in a female patient with the acquired immunodeficiency syndrome]. Med Clin (Barc). 1990 Dec 01; 95(19):754-5.
    View in: PubMed
    Score: 0.095
  16. Tie2/TEK modulates the interaction of glioma and brain tumor stem cells with endothelial cells and promotes an invasive phenotype. Oncotarget. 2010 Dec; 1(8):700-709.
    View in: PubMed
    Score: 0.095
  17. RB-E2F1: molecular rheostat for autophagy and apoptosis. Autophagy. 2010 Nov; 6(8):1216-7.
    View in: PubMed
    Score: 0.095
  18. Advances in translational research in neuro-oncology. Arch Neurol. 2011 Mar; 68(3):303-8.
    View in: PubMed
    Score: 0.094
  19. The RB-E2F1 pathway regulates autophagy. Cancer Res. 2010 Oct 15; 70(20):7882-93.
    View in: PubMed
    Score: 0.093
  20. [Internuclear ophthalmoplegia related to opiate overdose]. Med Clin (Barc). 1990 Apr 28; 94(16):637.
    View in: PubMed
    Score: 0.091
  21. Oncolytic adenovirus: preclinical and clinical studies in patients with human malignant gliomas. Curr Gene Ther. 2009 Oct; 9(5):422-7.
    View in: PubMed
    Score: 0.087
  22. Tie2-mediated multidrug resistance in malignant gliomas is associated with upregulation of ABC transporters. Oncogene. 2009 Jun 18; 28(24):2358-63.
    View in: PubMed
    Score: 0.085
  23. Autophagy pathways in glioblastoma. Methods Enzymol. 2009; 453:273-86.
    View in: PubMed
    Score: 0.083
  24. Oncolytic adenovirus retargeted to Delta-EGFR induces selective antiglioma activity. Cancer Gene Ther. 2009 Mar; 16(3):256-65.
    View in: PubMed
    Score: 0.082
  25. VEGF Trap induces antiglioma effect at different stages of disease. Neuro Oncol. 2008 Dec; 10(6):940-5.
    View in: PubMed
    Score: 0.081
  26. Tie2: a journey from normal angiogenesis to cancer and beyond. Histol Histopathol. 2008 06; 23(6):773-80.
    View in: PubMed
    Score: 0.080
  27. E2F1 in gliomas: a paradigm of oncogene addiction. Cancer Lett. 2008 May 18; 263(2):157-63.
    View in: PubMed
    Score: 0.079
  28. Delta-24-RGD in combination with RAD001 induces enhanced anti-glioma effect via autophagic cell death. Mol Ther. 2008 Mar; 16(3):487-93.
    View in: PubMed
    Score: 0.078
  29. Adenovirus-based strategies overcome temozolomide resistance by silencing the O6-methylguanine-DNA methyltransferase promoter. Cancer Res. 2007 Dec 15; 67(24):11499-504.
    View in: PubMed
    Score: 0.077
  30. Adenovirus's last trick: you say lysis, we say autophagy. Autophagy. 2008 Jan; 4(1):118-20.
    View in: PubMed
    Score: 0.077
  31. Examination of the therapeutic potential of Delta-24-RGD in brain tumor stem cells: role of autophagic cell death. J Natl Cancer Inst. 2007 Sep 19; 99(18):1410-4.
    View in: PubMed
    Score: 0.076
  32. ICOVIR-5 shows E2F1 addiction and potent antiglioma effect in vivo. Cancer Res. 2007 Sep 01; 67(17):8255-63.
    View in: PubMed
    Score: 0.076
  33. Angiopoietin-2 decreases vascular endothelial growth factor expression by modulating HIF-1 alpha levels in gliomas. Oncogene. 2008 Feb 21; 27(9):1310-4.
    View in: PubMed
    Score: 0.076
  34. Combination of the oncolytic adenovirus ICOVIR-5 with chemotherapy provides enhanced anti-glioma effect in vivo. Cancer Gene Ther. 2007 Aug; 14(8):756-61.
    View in: PubMed
    Score: 0.075
  35. Transgenic E2F1 expression in the mouse brain induces a human-like bimodal pattern of tumors. Cancer Res. 2007 May 01; 67(9):4005-9.
    View in: PubMed
    Score: 0.074
  36. Expression of the receptor tyrosine kinase Tie2 in neoplastic glial cells is associated with integrin beta1-dependent adhesion to the extracellular matrix. Mol Cancer Res. 2006 Dec; 4(12):915-26.
    View in: PubMed
    Score: 0.072
  37. Oncolytic viruses and DNA-repair machinery: overcoming chemoresistance of gliomas. Expert Rev Anticancer Ther. 2006 Nov; 6(11):1585-92.
    View in: PubMed
    Score: 0.071
  38. A novel CRM1-dependent nuclear export signal in adenoviral E1A protein regulated by phosphorylation. FASEB J. 2006 Dec; 20(14):2603-5.
    View in: PubMed
    Score: 0.071
  39. E2F1 and telomerase: alliance in the dark side. Cell Cycle. 2006 May; 5(9):930-5.
    View in: PubMed
    Score: 0.069
  40. Oncolytic adenoviruses as antiglioma agents. Expert Rev Anticancer Ther. 2006 May; 6(5):697-708.
    View in: PubMed
    Score: 0.069
  41. Sustained angiopoietin-2 expression disrupts vessel formation and inhibits glioma growth. Neoplasia. 2006 May; 8(5):419-28.
    View in: PubMed
    Score: 0.069
  42. Expression of transcription factor E2F1 and telomerase in glioblastomas: mechanistic linkage and prognostic significance. J Natl Cancer Inst. 2005 Nov 02; 97(21):1589-600.
    View in: PubMed
    Score: 0.067
  43. Downmodulation of E1A protein expression as a novel strategy to design cancer-selective adenoviruses. Neoplasia. 2005 Aug; 7(8):723-9.
    View in: PubMed
    Score: 0.066
  44. Delta24-hyCD adenovirus suppresses glioma growth in vivo by combining oncolysis and chemosensitization. Cancer Gene Ther. 2005 Mar; 12(3):284-94.
    View in: PubMed
    Score: 0.064
  45. Comparative effect of oncolytic adenoviruses with E1A-55 kDa or E1B-55 kDa deletions in malignant gliomas. Neoplasia. 2005 Jan; 7(1):48-56.
    View in: PubMed
    Score: 0.063
  46. Robust infectivity and replication of Delta-24 adenovirus induce cell death in human medulloblastoma. Cancer Gene Ther. 2004 Nov; 11(11):713-20.
    View in: PubMed
    Score: 0.062
  47. Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway. J Natl Cancer Inst. 2003 May 07; 95(9):652-60.
    View in: PubMed
    Score: 0.056
  48. Mechanisms underlying PTEN regulation of vascular endothelial growth factor and angiogenesis. Ann Neurol. 2003 Jan; 53(1):109-17.
    View in: PubMed
    Score: 0.055
  49. Overexpression of E2F-1 leads to bax-independent cell death in human glioma cells. Int J Oncol. 2002 Nov; 21(5):1015-20.
    View in: PubMed
    Score: 0.054
  50. Transfer of E2F-1 to human glioma cells results in transcriptional up-regulation of Bcl-2. Cancer Res. 2001 Sep 15; 61(18):6693-7.
    View in: PubMed
    Score: 0.050
  51. Adenovirally-mediated transfer of E2F-1 potentiates chemosensitivity of human glioma cells to temozolomide and BCNU. Int J Oncol. 2001 Aug; 19(2):359-65.
    View in: PubMed
    Score: 0.050
  52. [Oncolytic adenovirus for the treatment of cerebral tumors: past, present and future]. Neurologia. 2001 Mar; 16(3):122-7.
    View in: PubMed
    Score: 0.048
  53. Co-expression of E2F-2 enhances the p53 anti-cancer effect in human glioma cells. Int J Oncol. 2001 Feb; 18(2):343-7.
    View in: PubMed
    Score: 0.048
  54. Delivery of cell cycle genes to block astrocytoma growth. J Neurooncol. 2001 Feb; 51(3):277-87.
    View in: PubMed
    Score: 0.048
  55. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene. 2000 Jan 06; 19(1):2-12.
    View in: PubMed
    Score: 0.045
  56. Targeting in gene therapy for gliomas. Arch Neurol. 1999 Apr; 56(4):445-8.
    View in: PubMed
    Score: 0.042
  57. Gene therapy for gliomas: p53 and E2F-1 proteins and the target of apoptosis. Int J Mol Med. 1999 Jan; 3(1):81-5.
    View in: PubMed
    Score: 0.042
  58. The functional role of tumor suppressor genes in gliomas: clues for future therapeutic strategies. Neurology. 1998 Nov; 51(5):1250-5.
    View in: PubMed
    Score: 0.041
  59. Overexpression of E2F-1 in glioma triggers apoptosis and suppresses tumor growth in vitro and in vivo. Nat Med. 1998 Jun; 4(6):685-90.
    View in: PubMed
    Score: 0.040
  60. Suppression of human glioma growth by adenovirus-mediated Rb gene transfer. Neurology. 1998 May; 50(5):1307-15.
    View in: PubMed
    Score: 0.040
  61. Adenovirus-mediated p16 transfer to glioma cells induces G1 arrest and protects from paclitaxel and topotecan: implications for therapy. Int J Oncol. 1998 Mar; 12(3):665-9.
    View in: PubMed
    Score: 0.039
  62. Characterization of p53 and p21 functional interactions in glioma cells en route to apoptosis. J Natl Cancer Inst. 1997 Jul 16; 89(14):1036-44.
    View in: PubMed
    Score: 0.038
  63. Hypermethylation of the CpG island of p16/CDKN2 correlates with gene inactivation in gliomas. Oncogene. 1996 Oct 17; 13(8):1615-9.
    View in: PubMed
    Score: 0.036
  64. Adenovirus-mediated transfer of the p53 gene produces rapid and generalized death of human glioma cells via apoptosis. Cancer Res. 1996 Feb 15; 56(4):694-9.
    View in: PubMed
    Score: 0.034
  65. Adenovirus-mediated p16/CDKN2 gene transfer induces growth arrest and modifies the transformed phenotype of glioma cells. Oncogene. 1996 Jan 04; 12(1):103-10.
    View in: PubMed
    Score: 0.034
  66. Delta-24-RGD Induces Cytotoxicity of Glioblastoma Spheroids in Three Dimensional PEG Microwells. IEEE Trans Nanobioscience. 2015 Dec; 14(8):946-51.
    View in: PubMed
    Score: 0.034
  67. A frequent polymorphism in exon 1 of the p16/CDKN2 gene. Mol Cell Probes. 1995 Dec; 9(6):465-6.
    View in: PubMed
    Score: 0.034
  68. The oncolytic adenovirus ?24-RGD in combination with cisplatin exerts a potent anti-osteosarcoma activity. J Bone Miner Res. 2014 Oct; 29(10):2287-96.
    View in: PubMed
    Score: 0.031
  69. Melatonin-induced methylation of the ABCG2/BCRP promoter as a novel mechanism to overcome multidrug resistance in brain tumour stem cells. Br J Cancer. 2013 May 28; 108(10):2005-12.
    View in: PubMed
    Score: 0.028
  70. Paraneoplastic syndromes. Neurology. 1993 Jan; 43(1):236.
    View in: PubMed
    Score: 0.027
  71. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy. 2012 Apr; 8(4):445-544.
    View in: PubMed
    Score: 0.026
  72. [Paraneoplastic encephalomyelitis and Lambert-Eaton syndrome]. Rev Neurol (Paris). 1992; 148(10):605-9.
    View in: PubMed
    Score: 0.026
  73. Genetic and epigenetic modifications of Sox2 contribute to the invasive phenotype of malignant gliomas. PLoS One. 2011; 6(11):e26740.
    View in: PubMed
    Score: 0.025
  74. [Bezafibrate-induced necrotizing myopathy]. Med Clin (Barc). 1991 Mar 23; 96(11):439.
    View in: PubMed
    Score: 0.024
  75. Human adenovirus type 5 induces cell lysis through autophagy and autophagy-triggered caspase activity. J Virol. 2011 May; 85(10):4720-9.
    View in: PubMed
    Score: 0.024
  76. Reduction of nontarget infection and systemic toxicity by targeted delivery of conditionally replicating viruses transported in mesenchymal stem cells. Cancer Gene Ther. 2010 Apr; 17(4):289-97.
    View in: PubMed
    Score: 0.022
  77. Oncolytic adenoviruses for malignant glioma therapy. Front Biosci. 2003 May 01; 8:d577-88.
    View in: PubMed
    Score: 0.014
  78. Inhibition of breast cancer growth in vivo by antiangiogenesis gene therapy with adenovirus-mediated antisense-VEGF. Br J Cancer. 2001 May 04; 84(9):1252-7.
    View in: PubMed
    Score: 0.012
  79. Gene therapy for gliomas: molecular targets, adenoviral vectors, and oncolytic adenoviruses. Exp Cell Res. 1999 Oct 10; 252(1):1-12.
    View in: PubMed
    Score: 0.011
  80. Antiangiogenesis treatment for gliomas: transfer of antisense-vascular endothelial growth factor inhibits tumor growth in vivo. Cancer Res. 1999 Feb 15; 59(4):895-900.
    View in: PubMed
    Score: 0.010
  81. Adenovirus-mediated p16/CDKN2 gene transfer suppresses glioma invasion in vitro. Oncogene. 1997 Oct 23; 15(17):2049-57.
    View in: PubMed
    Score: 0.010
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.